دورية أكاديمية
أعرض في EDS

Protective effect of quercetin in ecto-enzymes, cholinesterases, and myeloperoxidase activities in the lymphocytes of rats exposed to cadmium.

التفاصيل البيبلوغرافية
العنوان: Protective effect of quercetin in ecto-enzymes, cholinesterases, and myeloperoxidase activities in the lymphocytes of rats exposed to cadmium.
المؤلفون: Abdalla FH; Programa de Pós Graduação em Ciências Biológicas: Bioquímica Toxicológica, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Campus Universitário, Camobi, Santa Maria, RS, 97105-900, Brazil, faha.biomed@hotmail.com., Cardoso AM, Schmatz R, Gonçalves JF, Baldissarelli J, Martins CC, Zanini D, de Oliveira LS, da Costa P, Pimentel VC, Pereira LB, Lhamas CL, Schetinger MR, Morsch VM, Mazzanti CM
المصدر: Molecular and cellular biochemistry [Mol Cell Biochem] 2014 Nov; Vol. 396 (1-2), pp. 201-11. Date of Electronic Publication: 2014 Jul 27.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: Netherlands NLM ID: 0364456 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-4919 (Electronic) Linking ISSN: 03008177 NLM ISO Abbreviation: Mol Cell Biochem Subsets: MEDLINE
أسماء مطبوعة: Publication: New York : Springer
Original Publication: The Hague, Dr. W. Junk B. V. Publishers.
مواضيع طبية MeSH: Cadmium/*toxicity , Cholinesterases/*metabolism , Lymphocytes/*drug effects , Peroxidase/*metabolism , Quercetin/*pharmacology, Acetylcholinesterase/metabolism ; Adenosine Deaminase/metabolism ; Animals ; Butyrylcholinesterase/blood ; Dose-Response Relationship, Drug ; Hydrolysis ; Lymphocytes/metabolism ; Male ; Protective Agents/pharmacology ; Pyrophosphatases/metabolism ; Rats, Wistar ; Toxicity Tests/methods
مستخلص: The ex vivo and in vitro effects of quercetin on NTPDase, adenosine deaminase (ADA), and acetycholinesterase (AChE) activities in lymphocytes, as well as the effects of quercetin on butyrylcholinesterase (BChE) activity in serum and myeloperoxidase (MPO) activity in plasma were determined in rats. For the ex vivo experiment, animals were orally exposed to Cadmium (Cd) for 45 days. Animals were divided into eight groups: saline/ethanol, saline/Querc 5 mg/kg, saline/Querc 25 mg/kg, saline/Querc 50 mg/kg, Cd/ethanol, Cd/Querc 5 mg/kg, Cd/Querc 25 mg/kg, and Cd/Querc 50 mg/kg. The ex vivo data showed an increase in the ATP and ADP hydrolysis and ADA activity in Cd-exposed rats when compared to the control group. The treatment with quercetin 25 and 50 mg/kg prevented this increase in the ATP and ADP hydrolysis, while the treatment with quercetin 5, 25, and 50 mg/kg prevented the increase in the ADA activity. AChE, BChE, and MPO activities ex vivo presented an increase in the Cd-exposed group when compared to the control group, and the treatment with quercetin 5, 25, and 50 mg/kg prevented this increase caused by Cd exposure. The in vitro experiment showed that quercetin 5, 10, 25, or 50 µM decreased the ADA activity proportionally to the increase of the concentrations of quercetin when compared to the control group. Thus, we can suggest that the quercetin is able to modulate NTPDase, ADA, AChE, and MPO activities and contribute to maintain the levels of ATP, adenosine, and acetylcholine normal, respectively, exhibiting potent pro-inflammatory and anti-inflammatory actions.
References: Toxicol Appl Pharmacol. 2003 Feb 1;186(3):163-88. (PMID: 12620369)
Food Chem Toxicol. 2004 Oct;42(10):1563-71. (PMID: 15304303)
J Biol Regul Homeost Agents. 2001 Jul-Sep;15(3):286-93. (PMID: 11693438)
Toxicol Appl Pharmacol. 2009 Aug 1;238(3):201-8. (PMID: 19409405)
J Physiol Biochem. 2003 Mar;59(1):43-8. (PMID: 12903904)
J Clin Invest. 2006 Jul;116(7):1835-7. (PMID: 16823484)
J Basic Clin Physiol Pharmacol. 2007;18(1):37-48. (PMID: 17569245)
Nano Lett. 2005 Apr;5(4):649-53. (PMID: 15826103)
Springer Semin Immunopathol. 2005 Jan;26(3):231-46. (PMID: 15609001)
Behav Brain Res. 2006 Aug 10;171(2):251-60. (PMID: 16707173)
J Am Diet Assoc. 2002 Oct;102(10):1414-20. (PMID: 12396158)
Mol Cell Biochem. 2013 Sep;381(1-2):1-8. (PMID: 23797318)
Curr Med Chem. 2008;15(12):1209-28. (PMID: 18473814)
J Membr Biol. 2010 Apr;234(3):227-34. (PMID: 20352203)
Scand J Work Environ Health. 1998;24 Suppl 1:1-51. (PMID: 9569444)
Enzyme. 1971;12(4):417-25. (PMID: 5316093)
Clin Exp Immunol. 2004 Oct;138(1):14-20. (PMID: 15373900)
J Immunol. 2009 Mar 1;182(5):2898-908. (PMID: 19234185)
J Exp Med. 2007 Jun 11;204(6):1257-65. (PMID: 17502665)
Eur J Pharmacol. 2003 Dec 15;482(1-3):281-5. (PMID: 14660033)
Anal Biochem. 1986 Sep;157(2):375-80. (PMID: 2946250)
N Engl J Med. 2000 Jul 13;343(2):108-17. (PMID: 10891520)
Clin Vaccine Immunol. 2006 Mar;13(3):319-28. (PMID: 16522772)
Nat Rev Immunol. 2011 Mar;11(3):201-12. (PMID: 21331080)
Int J Immunopharmacol. 1999 Jul;21(7):435-43. (PMID: 10454017)
Occup Environ Med. 2000 Oct;57(10):668-72. (PMID: 10984338)
Anal Biochem. 1976 May 7;72:248-54. (PMID: 942051)
J Occup Med Toxicol. 2006 Sep 10;1:22. (PMID: 16961932)
Neuropharmacology. 2006 Apr;50(5):540-7. (PMID: 16336980)
Purinergic Signal. 2006 Jun;2(2):409-30. (PMID: 18404480)
Eur J Pharmacol. 2005 Oct 3;521(1-3):9-20. (PMID: 16171798)
Phytochemistry. 2008 May;69(8):1739-44. (PMID: 18395762)
J Nutr. 2007 Oct;137(10):2190-5. (PMID: 17884996)
J Immunol. 1994 Oct 15;153(8):3574-83. (PMID: 7930580)
Life Sci. 2003 Dec 26;74(6):675-96. (PMID: 14654162)
Scand J Clin Lab Invest Suppl. 1968;97:77-89. (PMID: 4179068)
Blood. 1998 Nov 1;92(9):3007-17. (PMID: 9787133)
Biofactors. 2007;31(2):77-98. (PMID: 18806312)
Purinergic Signal. 2006 Jun;2(2):399-408. (PMID: 18404479)
Int J Dev Neurosci. 2009 Feb;27(1):73-80. (PMID: 18930802)
Biochem Pharmacol. 1961 Jul;7:88-95. (PMID: 13726518)
J Neuroimmunol. 2002 Nov;132(1-2):147-55. (PMID: 12417445)
Chem Biol Interact. 2010 Jun 7;186(1):53-60. (PMID: 20399762)
Mol Cell Biochem. 2003 Jan;243(1-2):153-60. (PMID: 12619901)
Cell Immunol. 2010;265(2):133-8. (PMID: 20832780)
Diabetes Res Clin Pract. 2006 Apr;72(1):28-32. (PMID: 16233931)
Fundam Appl Toxicol. 1993 Feb;20(2):210-6. (PMID: 8449393)
Pharmacol Ther. 2006 Nov;112(2):358-404. (PMID: 16784779)
Inhal Toxicol. 2009 Sep;21(11):906-12. (PMID: 19459774)
Biochim Biophys Acta. 2007 Sep;1770(9):1352-9. (PMID: 17643826)
Biochim Biophys Acta. 2005 Jan 18;1721(1-3):9-15. (PMID: 15652174)
Toxicol Lett. 2004 Sep 25;152(3):255-63. (PMID: 15331134)
Urol Oncol. 2013 Oct;31(7):1204-11. (PMID: 22137869)
Biol Pharm Bull. 2003 Oct;26(10):1398-402. (PMID: 14519943)
Biochem J. 1992 Jul 15;285 ( Pt 2):345-65. (PMID: 1637327)
Planta Med. 1996 Feb;62(1):20-1. (PMID: 8720382)
J Anal Toxicol. 1991 Mar-Apr;15(2):86-9. (PMID: 2051750)
Biometals. 2012 Dec;25(6):1195-206. (PMID: 22991071)
المشرفين على المادة: 0 (Protective Agents)
00BH33GNGH (Cadmium)
9IKM0I5T1E (Quercetin)
EC 1.11.1.7 (Peroxidase)
EC 3.1.1.7 (Acetylcholinesterase)
EC 3.1.1.8 (Butyrylcholinesterase)
EC 3.1.1.8 (Cholinesterases)
EC 3.5.4.4 (Adenosine Deaminase)
EC 3.6.1.- (Pyrophosphatases)
تواريخ الأحداث: Date Created: 20140728 Date Completed: 20151006 Latest Revision: 20211021
رمز التحديث: 20221213
DOI: 10.1007/s11010-014-2155-7
PMID: 25064450
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-4919
DOI:10.1007/s11010-014-2155-7